Shopping Cart
Remove All
Your shopping cart is currently empty
Romlusevimab
Copy Product Info
😃Good
Catalog No. T77165Cas No. 2509447-08-7
Alias BRII-198, BRII198
Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.
Romlusevimab
Romlusevimab
Copy Product Info😃Good
Catalog No. T77165Alias BRII-198, BRII198Cas No. 2509447-08-7
Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | - | In Stock | |
| 5 mg | $753 | - | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection. |
| In vitro | Romlusevimab showed a high binding affinity for RBD with an equilibrium dissociation constant (KD) of 0.56 nM. The mixture of Amubarvimab and Romlusevimab blocks the binding of human ACE2 receptor to RBD, IC50 = 16.36 nM. The neutralizing activity of Romlusevimab against Neut99 was 2.50 μg/mL. [1] |
| In vivo | Amubarvimab and Romlusevimab at a 1:1 mixture of 10 mg/kg or 50 mg/kg intritoneally injected into hamsters showed potent activity against SARS-CoV-2. [1] |
| Synonyms | BRII-198, BRII198 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Spike RBD |
| Molecular Weight | 143.4 kDa |
| Cas No. | 2509447-08-7 |
| Isotype | Human IgG1 lambda C2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Romlusevimab | purchase Romlusevimab | Romlusevimab cost | order Romlusevimab | Romlusevimab in vivo | Romlusevimab in vitro | Romlusevimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.